Revefenacin for the treatment of chronic obstructive pulmonary disease

References

• Wu YK, Su WL, Huang CY, et al. Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels. Medicine. 2018;97(47):e11922.
   Google Scholar
• Kaszuba E, Odeberg H, Råstam L, et al. Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study. BMC Fam Pract. 2018;19(1):178.
   PubMedGoogle Scholar
• Paulin LM, Diette GB, Blanc PD, et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(5):557–565.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Lobal strategy for the diagnosis, management and prevention of COPD(2019 report). [cited 2019 Mar 5]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
   Google Scholar
• Liu S, Zhou Y, Liu S, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: results from a cross-sectional study in China. Thorax. 2017;72(9):788–795.
   PubMed Web of Science ®Google Scholar
• Sana A, Somda SMA, Meda N, et al. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. BMJ Open Respir Res. 2018;5(1):e000246.
   PubMed Web of Science ®Google Scholar
• Gan WQ, FitzGerald JM, Carlsten C, et al. Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med. 2013;187(7):721–727.
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341–1351.
   PubMed Web of Science ®Google Scholar
• Aziz M, Tan LE, Wu DB, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203.
   Google Scholar
• Kisialiou A, Prinzi G, Lamonaca CV, et al. Pharmacological management of Chronic Obstructive Lung Disease (COPD). Evidence from a real-world perspective. Curr Med Chem. 2018 Oct 30. [Epub ahead of print].
   Google Scholar
• Lane DC, Stemkowski S, Stanford RH, et al. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172.
   PubMed Web of Science ®Google Scholar
• Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
   PubMed Web of Science ®Google Scholar
• Burkes RM, Drummond MB. Initiating drug therapy in early stage chronic obstructive pulmonary disease: does it impact the course and outcome? Curr Opin Pulm Med. 2019;25(2):132–137.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. YUPELRI (revefenacin) inhalation solution, for oral inhalation. [cited 2018 Dec 2]. Available from.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf.
   Google Scholar
• Kopsaftis ZA, Sulaiman NS, Mountain OD, et al. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review. Syst Rev. 2018;7(1):213–216.
   PubMedGoogle Scholar
• Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev. 2015;22(9):CD009552.
   PubMed Web of Science ®Google Scholar
• Disse B, Reichl R, Speck G, et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5-6):537–544.
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19(2):209–216.
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Roset M, Rodriguez-Blanco T, et al. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study. Int J Chron Obstruct Pulmon Dis. 2017;12:1145.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs . 2012;72(15):1999.
   PubMed Web of Science ®Google Scholar
• Gavaldà A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009;331(2):740–741.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Copd. 2012;9(2):90–91.
   PubMedGoogle Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. Epub. 2012;40(4):830–836.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. SEEBRI™ NEOHALER® (glycopyrrolate) inhalation powder, for oral inhalation use. [cited 2018 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207923lbl.pdf.
   Google Scholar
• Haddad EB, Patel H, Keeling JE, et al. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate,in human and guinea-pig airways. Br J Pharmacol . 1999;127(2):413–420.
   PubMed Web of Science ®Google Scholar
• Gavaldà A, Ramos I, Carcasona C, et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm Pharmacol Ther. 2014;28(2):114–121.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Gross NJ. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:1873–1878.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Cristiano A, et al. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Des Devel Ther. 2017;11:3257.
   PubMed Web of Science ®Google Scholar
• Durigan RC, Niedermier V. Umeclidinium (Incruse Ellipta) for COPD. Am Fam Physician. 2017;95(2):120–121.
   PubMed Web of Science ®Google Scholar
• Babu KS, Morjaria JB. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis . 2017;8(4–5):81–91.
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Gao J, et al. Inhaled Umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016;76(3):343–361.
   PubMed Web of Science ®Google Scholar
• Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36(3):164–171.
   PubMed Web of Science ®Google Scholar
• Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;(208):317–341.
   PubMedGoogle Scholar
• Kruse AC, Hu J, Pan AC, et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature. 2012;482(7386):552–556.
   PubMed Web of Science ®Google Scholar
• Mastrodicasa MA, Droege CA, Mulhall AM, et al. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opin Investig Drugs . 2017;26(2):161–164.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel,nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018;6(3):e00400.
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lungselective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–250.
   PubMed Web of Science ®Google Scholar
• Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52(4):pii: 1701247.
   Web of Science ®Google Scholar
• Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized,double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–79.
   PubMed Web of Science ®Google Scholar
• Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind,placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182–183.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Efficacy study of nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD). [cited 2018 Nov 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02459080?term=NCT02459080&rank=1.
   Google Scholar
• U.S. Food and Drug Administration. Drug approval package: yupelri (revefenacin). [cited 2019 Feb 30]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000SumR.pdf
   Google Scholar
• ClinicalTrials.gov. A phase 3, 12-week, randomized, double-blind placebo-controlled parallel group study of nebulized TD-4208 in subjects with chronic obstructive pulmonary disease. [cited 2018 Nov 30]. Available from https://clinicaltrials.gov/ct2/show/NCT02512510?term=NCT02512510&rank=1m.
   Google Scholar
• ClinicalTrials.gov.A phase 3, 52-week, randomized, active−controlled parallel group study to evaluate the safety and tolerability of nebulized TD−4208 in subjects with chronic obstructive pulmonary disease. [cited 2018 Nov 30]. Available from https://clinicaltrials.gov/ct2/show/NCT02518139?term=Revefenacin&draw=3&rank=6.
   Google Scholar
• Hess MW. The 2017 global initiative for chronic obstructive lung disease report and practice implications for the respiratory therapist. Respir Care. 2017;62(11):1492–1500.
   PubMed Web of Science ®Google Scholar
• Kolahian S, Gosens R. Cholinergic regulation of airway inflammation and remodelling. J Allergy (Cairo). 2012;2012:681258.
   PubMedGoogle Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2011;32(8):495–496.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585–2586.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109.
   PubMed Web of Science ®Google Scholar